Home LiteratureArticle Details
PMID: 339442 Published · ppublish English Clinical Trial Journal Article

Persistent immunoglobulinuria in irreversible renal allograft rejection in humans.

Transplantation ·Vol. 24 ·No. 6 ·1977-12-00 ·Pages 453-7

Kwun K, Bramis JP, Haimov M, Slifkin R, Glabman S, Burrows L

Abstract

To evaluate the extent of injury in short- and long-term renal allografts, the urinary excretion of IgG, IgA, and IgM was observed during acute rejection crisis. In reversible rejection, treatment resulted in prompt correction of immunoglobulinuria, whereas in irreversible crisis urinary immunoglobulin levels continuously increased in spite of the same antirejection treatment. A good prognosis in long-term allografts was shown by low levels of immunoglobulinuria; unstable graft function had higher levels. Immunoglobulinuria can be used as an additional test to evaluate the reversibility of acute rejection, and also has significance in the long-term situation.

MeSH Terms
Adult Cadaver Clinical Trials as Topic Double-Blind Method Female Graft Rejection/drug effects Humans Immunoglobulin A/urine Immunoglobulin G/urine Immunoglobulin M/urine Immunoglobulins/urine Immunosuppressive Agents/pharmacology Kidney Transplantation Male Prognosis Prospective Studies Time Factors Transplantation, Homologous
Chemicals
Immunoglobulin A Immunoglobulin G Immunoglobulin M Immunoglobulins Immunosuppressive Agents
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Kwun K
Bramis J P
Haimov M
Slifkin R
Glabman S
Burrows L
Article Info
Journal
Transplantation
Abbr.
Transplantation
ISSN
0041-1337
Published
1977-12-00
Pages
453-7
Language
English
Region
United States
NLM ID
0132144
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com